Ex head of European Medicines Agency (EMA) teams up with NDA
January 20, 2011With new drug development costs soaring the NDA Group launches a new regulatory and market access business that aims to …
Key drug launches for 2011
January 20, 2011Sales and Marketing Benlysta, Cladribine, Movectro, Pradaxa, Xarelto, axitinib, boceprevir, crizotinib, telaprevir
This year is expected to see new treatments for hepatitis C, multiple sclerosis and lupus among those that could reach …
Cancer Drugs Fund must not be forerunner to value-based pricing – EMIG
January 19, 2011Sales and Marketing Cancer Drugs Fund, EMIG, Ethical Medicines Industry Group, NHS, value-based pricing
The association representing small to medium UK pharma companies says the forthcoming Cancer Drugs Fund is welcome – but must …
Trial success for Roche’s personalised skin cancer drug
January 19, 2011Research and Development BRAF V600, Cancer, RG7204, Roche, personalised medicine, skin cancer
A promising Roche drug has helped previously untreated patients with advanced skin cancer to live longer without their disease getting …
EMA’s Thomas Lönngren joins market access firm
January 19, 2011Research and Development, Sales and Marketing NDA Group, Thomas Lönngren, appointment, recruitment, research and development, sales and marketing
The former head of the EMA Thomas Lönngren has taken up a post at new European regulatory and market access …
Sanofi ‘considering’ raising Genzyme offer
January 19, 2011Manufacturing and Production, Research and Development, Sales and Marketing Genzyme, Sanofi, Sanofi-Aventis, pharma mergers and acquisitions
Sanofi-Aventis could be willing to raise its offer to $76 a share to buy the US biotech firm Genzyme, according …
Success in pre-clinical microRNA treatment of prostate cancer
January 19, 2011Research and Development MD Anderson Cancer Center, MicroRNA, Mirna Therapeutics, RNA interfering, miRNA, prostate cancer, rnai
A new MicroRNA treatment for prostate cancer has been highly effective against the disease in pre-clinical studies. MicroRNAs, or miRNAs, …
Syntaxin appoints Russell Greig chairman
January 19, 2011Research and Development Russell Greig, appointment, research and development, syntaxin
Oxford, UK-based biotechnology company Syntaxin has appointed Dr Russell Greig as its new chairman.Russell has over 30 years experience in …
Online physician communities in UK and France join forces
January 19, 2011Medical Communications, Sales and Marketing Egora, Global Media Sante, doctors communities, doctors.net, online communities
Two online communities for doctors have launched a strategic alliance to help them expand their reach. UK-based Doctors.net.uk is teaming …
Double Helix appoints Hollie Durrance and Gavin Harper
January 18, 2011Medical Communications Double Helix, Gavin Harper, Hollie Durrance, appointment, medical communications
Global market research consultancy Double Helix has appointed Hollie Durrance as research manager and Gavin Harper as trainee research executive …
MPs hit out at NHS reforms
January 18, 2011GP consortia, Health Select Committee, NHS, NHS reforms, PCTs
MPs have come out against the NHS White Paper, saying it has caused wide spread uncertainty at a time when …
European Commission launches new generic deal review
January 18, 2011Sales and Marketing European Commission, anti-trust investigation, competition, generics
The European Commission has asked a number of firms to submit copies of their patent settlements in 2010 to see …
GSK takes £2.2bn hit from Avandia claims
January 18, 2011Sales and Marketing Avandia, GSK, GlaxoSmithKline, rosiglitazone
GlaxoSmithKline’s Avandia woes are continuing, with the company admitting it expects to take a mammoth legal charge over the troubled …
Merck Serono and Domain to co-develop Parkinson’s drugs
January 18, 2011Research and Development Domain Therapeutics, Merck KGaA, Merck Serono, PAM, Parkinson's disease, Parkinson’s disease, Positive Allosteric Modulator, mGluR4, metabotropic glutamate receptor 4
Merck Serono is to work with French biotech company Domain Therapeutics to develop a new treatment for Parkinson’s disease and …
Merck suffers late-stage blow to vorapaxar
January 18, 2011Research and Development ACS, Merck & Co, acute coronary syndrome, anticoagulant, heart attack, peripheral arterial disease, stroke, vorapaxar
An increased risk of bleeding caused by pipeline drug vorapaxar has dealt Merck a major blow.The Data and Safety Monitoring …
BMS and Sanofi recall 64 million Avalide tablets
January 18, 2011Manufacturing and Production Avalide, Avapro, Bristol-Myers Squibb, GMP, Good Manufacturing Practice, Sanofi-Aventis, hypertension, irbesartan
Bristol-Myers Squibb and Sanofi-Aventis have started another massive recall of their antihypertensive product Avalide because a manufacturing defect could affect …
Merck taps Parexel to help it meet biosimilar ambitions
January 18, 2011Research and Development Merck & Co, Parexel, biosimilars
Merck & Co has enlisted the aid of contract research organisation Parexel to help it develop biosimilar versions of some …
Top doctors believe PCTs should stay
January 17, 2011BMA, NHS, NHS reforms, PCTs, Royal College of GP
Leading GPs have criticised the government’s wide-ranging NHS reforms, saying minor structural changes are all the health service needs. A …
FDA issues Multaq liver warning
January 17, 2011Sales and Marketing FDA, Multaq, atrial fibrilation, dronedarone
US regulators have warned doctors and patients about the risk of severe liver injury associated with Sanofi-Aventis’ atrial fibrillation (AF) …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
